Amplia Therapeutics (ATX) AI Stock Analysis

• Market Cap: AU$66.70M
• Dividend Yield: N/A
• Average Volume (3M): 525.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: N/A
• EPS Growth: 26.64%
• Country: AU
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 513,071,660
• 10 Day Avg. Volume: 444,673
• 30 Day Avg. Volume: 525,217
• PEG Ratio: 0.42
• Price to Book (P/B): 1.02
• Price to Sales (P/S): 5.68
• P/FCF Ratio: -3.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: AU$0.13 ▼(-7.14% Downside)

The score is held down primarily by ongoing losses and weak cash generation, despite a relatively stable, low-leverage balance sheet. Technically, the stock is trading below key longer-term moving averages with only mild momentum. Valuation is also constrained by negative earnings and the absence of dividend yield.

Positive Factors

High gross margins

Gross margins above 90% indicate the company’s core activities have low direct costs versus revenue. For a biotech, this supports scalable economics for licensing or product sales later, allowing a higher proportion of funding to be directed to R&D and clinical programs over time.

Low financial leverage

A conservative balance sheet with low debt and a healthy equity base reduces solvency risk and preserves strategic optionality. This positions the company to endure multi-stage clinical programs and negotiate partnerships or funding without immediate pressure from creditors.

Focused oncology pipeline (FAK inhibitor)

A focused pipeline centered on a FAK inhibitor for solid tumors provides clear scientific differentiation and defined clinical development milestones. Concentration on a targeted mechanism and specified indications can attract partnerships and streamline resource allocation across trials.

Negative Factors

Negative operating and free cash flow

Sustained negative operating and free cash flows indicate ongoing burn to fund R&D and trials. Over the coming months this structural cash deficit increases reliance on external financing or partnerships, which can dilute shareholders or constrain program timelines if funding is delayed.

Ongoing net losses and negative margins

Persistent negative profitability metrics reflect that the company remains in development-stage spending mode. Until clinical or commercial milestones generate revenue, negative margins will limit return generation and maintain dependence on capital markets for sustaining operations.

Very small operating scale

A one-person headcount signals minimal internal operational capacity and heavy reliance on external contractors or partners. This raises execution risk for complex clinical programs, may slow trial progress, and increases vulnerability to delays or coordination failures over the medium term.

Amplia Therapeutics Business Overview & Revenue Model

Company Description

Amplia Therapeutics (ATX) is a biotechnology company focused on developing innovative therapies for the treatment of fibrotic diseases and cancer. The company specializes in the discovery and development of small molecule drugs that target the underlying biological processes driving these conditions. Amplia's core products include its lead drug candidate, which is designed to inhibit specific pathways involved in fibrosis, thereby offering potential benefits for patients suffering from these debilitating diseases.

How the Company Makes Money

Amplia Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company's revenue model includes funding from grants and research partnerships, which support the clinical development of its therapies. Additionally, Amplia may enter into licensing agreements or partnerships with larger pharmaceutical companies, allowing them to share in the development costs and potential profits from successful drug candidates. Revenue can also be derived from milestone payments and royalties based on sales once products are commercialized. Furthermore, the company may attract investment through equity financing to support its ongoing research and development efforts.

Amplia Therapeutics Financial Statement Overview

Summary

Mixed financials typical of a development-stage biotech: very strong gross margins and some revenue growth, but continued losses (negative net/EBIT/EBITDA margins). Balance sheet leverage is low with a healthy equity base, yet return on equity is negative. Cash flow remains a key weakness with negative operating and free cash flow.

Income Statement

Amplia Therapeutics shows a mixed performance in its income statement. The company has a strong gross profit margin, consistently above 90%, indicating efficient cost management. However, the net profit margin is negative, reflecting ongoing losses, which is common in the biotechnology industry due to high R&D expenses. Revenue growth is positive, but the company has not yet achieved profitability, as evidenced by negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet of Amplia Therapeutics is relatively stable, with a low debt-to-equity ratio, suggesting conservative leverage. However, the return on equity is negative, indicating that the company is not generating profits from its equity base. The equity ratio is healthy, showing a strong equity position relative to total assets, which provides a buffer against financial instability.

Cash Flow

Amplia Therapeutics faces challenges in its cash flow statement. The company has negative operating and free cash flows, which are typical for biotech firms in the development stage. The free cash flow to net income ratio is close to 1, indicating that cash outflows are closely aligned with reported losses. Despite a significant increase in free cash flow growth, the overall cash flow position remains weak.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.38M	3.78M	4.45M	1.19M	1.98M	1.53M
Gross Profit	2.20M	3.57M	4.01M	1.12M	1.98M	1.53M
EBITDA	-10.75M	-6.78M	-4.48M	-7.26M	-3.64M	-3.81M
Net Income	-7.93M	-6.57M	-4.50M	-6.24M	-3.64M	-2.28M
Balance Sheet
Total Assets	44.54M	22.94M	14.85M	18.68M	24.48M	10.88M
Cash, Cash Equivalents and Short-Term Investments	29.16M	10.86M	3.39M	9.26M	14.61M	1.85M
Total Debt	381.42K	13.89K	1.59M	2.27M	2.10M	0.00
Total Liabilities	1.61M	1.91M	3.43M	2.85M	2.64M	539.13K
Stockholders Equity	42.93M	21.02M	11.42M	15.84M	21.85M	10.34M
Cash Flow
Free Cash Flow	-13.39M	-6.89M	-5.13M	-5.31M	-4.42M	-2.92M
Operating Cash Flow	-13.36M	-6.89M	-5.13M	-5.29M	-4.40M	-2.92M
Investing Cash Flow	-81.65K	-2.07K	-2.23K	-58.42K	-26.64K	-5.35K
Financing Cash Flow	37.99M	14.32M	-772.98K	-84.22K	17.19M	3.66M

Amplia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ATX, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.14, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.69 is Neutral, neither overbought nor oversold. The STOCH value of 26.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ATX.

Amplia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NC6	48 Neutral	AU$23.18M	-10.44	-1651.76%	―	-100.00%	2.86%
CMB	48 Neutral	AU$13.78M	-2.33	-166.70%	―	―	―
AVE	44 Neutral	AU$33.06M	-9.09	-143.71%	―	306.88%	―
ATX	43 Neutral	AU$66.70M	-6.47	-27.39%	―	―	26.64%
NOX	42 Neutral	AU$19.00M	-3.89	-157.93%	―	―	-36.89%
1AD	37 Underperform	AU$11.47M	-1.61	-628.72%	―	―	31.87%

Amplia Therapeutics Corporate Events

Amplia Secures Phase 3-Ready Supply with First Large-Scale Narmafotinib Manufacture

Amplia Therapeutics has completed the first large-scale, GMP-compliant manufacture of narmafotinib, producing about 13 kilograms of active pharmaceutical ingredient and successfully transitioning production from an R&D setting to a commercial-ready environment. The scale-up, achieved in collaboration with a contract development and manufacturing partner, has generated cost efficiencies and ensures sufficient drug supply to support Amplia’s ongoing and planned pancreatic cancer trials and other studies, marking a key step toward Phase 3 readiness and strengthening the company’s clinical development pipeline and future registrational strategy.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Showcases Promising Pancreatic Cancer Data for Narmafotinib at ASCO GI

Amplia Therapeutics has reported updated interim data from its Phase 2a ACCENT trial in metastatic pancreatic cancer, presented at the 2026 ASCO Gastrointestinal Cancer Symposium. The trial, which evaluates narmafotinib in combination with standard chemotherapies gemcitabine and Abraxane, shows a progression-free survival of 7.7 months versus 5.5 months for chemotherapy alone and an overall response rate of 35%, rising to 42% including unconfirmed responses, while maintaining a safety profile comparable to chemotherapy alone. Management says the ASCO GI presentation reinforces Amplia’s positioning among leading oncology developers and highlights the potential of narmafotinib to improve outcomes in advanced pancreatic cancer, complementing its broader clinical strategy that includes the newly opened AMPLICITY trial combining narmafotinib with FOLFIRINOX.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Deepens Next & Bio Collaboration to Test Narmafotinib–kRAS Combo in Pancreatic Cancer

Amplia Therapeutics has entered a second phase of its preclinical research collaboration with Korean drug screening specialist Next & Bio to further investigate the effects of its FAK inhibitor narmafotinib in combination with experimental kRAS inhibitors on patient-derived pancreatic cancer cells. The extension follows encouraging initial data showing narmafotinib’s activity against kRAS-mutant pancreatic cancer models, and the partners will now explore potential synergistic effects with kRAS inhibitors, a new class of drugs under development for several solid tumours. Amplia sees this next stage as an opportunity to strengthen its scientific case for combination therapies in hard-to-treat pancreatic cancer, enhance the clinical and commercial prospects of narmafotinib and potentially broaden partnering opportunities, while Next & Bio leverages its advanced patient-derived cell platform to support the development of new treatment options in an area of high unmet medical need.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Reports Positive ACCENT Trial Results for Pancreatic Cancer

Amplia Therapeutics announced a positive development in its ACCENT trial for metastatic pancreatic cancer, where its FAK inhibitor narmafotinib, combined with gemcitabine and nab-paclitaxel, achieved a 35% objective response rate. This result surpasses the 23% response rate of the benchmark MPACT trial, indicating a significant advancement in treatment efficacy. The data will be presented at the Life Sciences Virtual Investor Forum, highlighting Amplia’s potential impact on cancer treatment and its strategic positioning in the pharmaceutical industry.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Reports Promising Trial Results for Pancreatic Cancer Drug

Amplia Therapeutics has announced its financial report for the half year ending September 2025, highlighting significant progress in its clinical trials. The company’s lead drug, narmafotinib, has shown promising results in the ACCENT trial for advanced pancreatic cancer, achieving a confirmed response rate of 33%, which is superior to existing treatments. A new trial, AMPLICITY, has also commenced, further exploring narmafotinib’s efficacy in combination with FOLFIRINOX.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.11 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Receives FDA Support for Pancreatic Cancer Trial

Amplia Therapeutics has received positive feedback from the US FDA regarding its planned Phase 2b/3 trial for narmafotinib, a FAK inhibitor, in combination with gemcitabine and Abraxane for pancreatic cancer. The FDA’s support for the dose comparison design and minimal impact on timelines enhances Amplia’s confidence in proceeding with the trial, which is set to begin in late 2026, potentially strengthening its position in the oncology market.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Issues New Equity Securities

Amplia Therapeutics Limited has announced the issuance of 480,769 unquoted equity securities in the form of Zero Exercise Price Options under an employee incentive scheme. This strategic move is likely aimed at retaining and motivating employees, potentially impacting the company’s operational efficiency and competitive positioning in the biotechnology sector.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Expands U.S. Market Presence with OTCQB Listing

Amplia Therapeutics has commenced trading on the U.S. OTCQB Venture Market, enhancing its engagement with U.S. investors and expanding its presence in the U.S. market. This move coincides with the company’s AMPLICITY clinical trial for advanced pancreatic cancer opening at five sites in the U.S., and is part of Amplia’s broader strategy to educate investors about its FAK inhibitor program, which includes the promising drug narmafotinib.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Advances Narmafotinib Trials with Promising Results

Amplia Therapeutics has reported significant progress in its clinical trials for narmafotinib, a FAK inhibitor, showing improved outcomes in metastatic pancreatic cancer treatment. The company has achieved key regulatory milestones, including ethics approval for a new trial combining narmafotinib with FOLFIRINOX chemotherapy and securing a patent for its drug formulation, positioning it for further commercial development and potential partnerships.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Secures $3.77 Million R&D Tax Rebate to Boost Cancer Trials

Amplia Therapeutics has received a $3.77 million R&D tax rebate from the Australian Tax Office, which will support the progression of its clinical trials for narmafotinib, a FAK inhibitor. This funding will aid in advancing the ACCENT and AMPLICITY trials, which are exploring narmafotinib’s effectiveness in treating advanced pancreatic cancer, potentially enhancing Amplia’s position in the oncology pharmaceutical industry.

The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.